Allogene CAR-Ts’ Durability Remains A Question, But Strong Data So Far
Pivotal Trial Likely To Include Consolidation Dosing
Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.
You may also be interested in...
Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.
Giving cell therapies as outpatient rather than inpatient treatments could be a way around the need for bundled payments, but it’s not universally applicable.